Plus Therapeutics, Inc.
PSTV
$5.50
-$0.03-0.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.93% | -3.19% | -4.05% | 8.68% | -36.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.93% | -3.19% | -4.05% | 8.68% | -36.85% |
| Cost of Revenue | 63.15% | 34.54% | -14.77% | -55.07% | -36.45% |
| Gross Profit | -163.56% | -103.36% | 25.89% | 109.64% | 35.82% |
| SG&A Expenses | 86.05% | 33.33% | 43.64% | -23.65% | 28.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 77.30% | 33.83% | 11.87% | -41.16% | -7.66% |
| Operating Income | -101.33% | -47.23% | -17.98% | 58.40% | -7.18% |
| Income Before Tax | 60.08% | -46.37% | -53.90% | 275.20% | -433.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 60.08% | -46.37% | -53.90% | 275.20% | -433.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.08% | -46.37% | -53.90% | 275.20% | -433.61% |
| EBIT | -101.33% | -47.23% | -17.98% | 58.40% | -7.18% |
| EBITDA | -107.17% | -57.57% | -22.36% | 58.58% | -7.82% |
| EPS Basic | 96.50% | 91.64% | 88.75% | 105.44% | -58.31% |
| Normalized Basic EPS | 96.50% | 91.64% | 88.75% | 123.54% | -58.31% |
| EPS Diluted | 96.50% | 91.53% | 88.87% | 99.08% | -58.31% |
| Normalized Diluted EPS | 96.50% | 91.64% | 88.75% | 109.00% | -58.31% |
| Average Basic Shares Outstanding | 1,040.55% | 1,650.57% | 1,267.66% | 644.46% | 237.02% |
| Average Diluted Shares Outstanding | 1,040.55% | 1,650.57% | 1,267.66% | 1,846.99% | 237.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |